WO2013050748A2 - Procédé de préparation amélioré de buprénorphine - Google Patents

Procédé de préparation amélioré de buprénorphine Download PDF

Info

Publication number
WO2013050748A2
WO2013050748A2 PCT/GB2012/052423 GB2012052423W WO2013050748A2 WO 2013050748 A2 WO2013050748 A2 WO 2013050748A2 GB 2012052423 W GB2012052423 W GB 2012052423W WO 2013050748 A2 WO2013050748 A2 WO 2013050748A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
solution
alkyl
norbuprenorphine
Prior art date
Application number
PCT/GB2012/052423
Other languages
English (en)
Other versions
WO2013050748A3 (fr
Inventor
Nicholas Archer
David AUGUST
Michael BEASE
Barbara JAMIESON
Robert S. Marmor
Original Assignee
Johnson Matthey Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB1407259.9A priority Critical patent/GB2509659B/en
Priority to CA2849988A priority patent/CA2849988C/fr
Priority to US14/349,213 priority patent/US9624231B2/en
Priority to IN3197CHN2014 priority patent/IN2014CN03197A/en
Priority to AU2012320291A priority patent/AU2012320291B2/en
Priority to ES12775287.1T priority patent/ES2692885T3/es
Application filed by Johnson Matthey Plc filed Critical Johnson Matthey Plc
Priority to EP17199667.1A priority patent/EP3321269B1/fr
Priority to EP12775287.1A priority patent/EP2763996B1/fr
Publication of WO2013050748A2 publication Critical patent/WO2013050748A2/fr
Publication of WO2013050748A3 publication Critical patent/WO2013050748A3/fr
Priority to ZA2014/02624A priority patent/ZA201402624B/en
Priority to US15/489,146 priority patent/US10208054B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms

Definitions

  • the present invention provides a process for the production of opiate alkaloids.
  • the present invention provides an improved process for the production of buprenorphine or a derivative of buprenorphine that increases overall yield and reduces impurities.
  • Buprenorphine is a semisynthetic opiate used medicinally as a powerful analgesic, indicated for the treatment of moderate to severe pain and opioid dependence.
  • the preparation of buprenorphine from thebaine is known and has been reported in publications to be carried out by the following 6 major step scheme:
  • the presently known method for preparing buprenorphine has several drawbacks.
  • the method is an unspecific reaction scheme, that is, the method produces many other unwanted products, i.e., impurities, along with the buprenorphine.
  • the buprenorphine has to be isolated and purified, which is time consuming and inefficient. Attempts have been made by others to improve the method of preparing
  • CMB cyanamide- norbuprenorphine-3 -methyl ether
  • NME Norbuprenorphine 3-Methyl Ether
  • NOC Norbuprenorphine crude
  • NOP Norbuprenorphine pure
  • the point of attachment of a moiety or substituent is represented by For example, -OH is attached through the oxygen atom.
  • Alkyl refers to a straight-chain, branched or cyclic saturated hydrocarbon group.
  • the alkyl group may have from 1-20 carbon atoms, in certain embodiments from 1-15 carbon atoms, in certain embodiments, 1-8 carbon atoms.
  • the alkyl group may be unsubstituted or substituted. Unless otherwise specified, the alkyl group may be attached at any suitable carbon atom and, if substituted, may be substituted at any suitable atom.
  • Typical alkyl groups include but are not limited to methyl, ethyl, n- propyl, iso-propyl, cyclopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, cyclobutyl, n- pentyl, cyclopentyl, n-hexyl, cyclohexyl and the like.
  • Aryl refers to an aromatic carbocyclic group.
  • the aryl group may have a single ring or multiple condensed rings.
  • the aryl group can have from 6- 20 carbon atoms, in certain embodiments from 6-15 carbon atoms, in certain embodiments, 6-12 carbon atoms.
  • the aryl group may be unsubstituted or substituted. Unless otherwise specified, the aryl group may be attached at any suitable carbon atom and, if substituted, may be substituted at any suitable atom. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl and the like.
  • Arylalkyl refers to an optionally substituted group of the formula aryl-alkyl-, where aryl and alkyl are as defined above.
  • Halo or "halogen” refers to -F, -CI, -Br and -I.
  • Morphinan refers to a compound comprising the core structure:
  • Substituted refers to a group in which one or more (e.g. 1 , 2, 3, 4 or 5) hydrogen atoms are each independently replaced with substituents which may be the same or different.
  • the substituent may be any group which tolerates the demethylation reaction conditions. Examples of substituents include but are not limited to -R a , -0-R a , -S-R a , - NR a R and -NHR a ; wherein R a and R D are independently selected from the groups consisting of alkyl, aryl and arylalkyl, and wherein R a and R b may be unsubstituted or further substituted as defined herein.
  • an improved method for the preparation of buprenorphine that improves the overall yield of buprenorphine, and reduces the formation of impurities.
  • Reduction of the formation of impurities is significant, as the process heretofore known in the art is prone to produce a great amount of impurities which requires purification and isolation processes.
  • Production of the impurities is believed to result in part from decomposition. It has been found by the present inventors that significant formation of impurities, and large yield losses occur during step 5 of the prior art buprenorphine reaction scheme.
  • the improved method of preparing buprenorphine includes two separate reaction steps after stage 4 of the process. It has been found that this modification to the prior art process for making buprenorphine can occur at relatively mild conditions, and improves both overall yield of the product and reduces impurities formation. In some embodiments, a purification step is optional and not necessary.
  • the improved method for preparing buprenorphine includes the following reaction steps shown below:
  • Step 1 comprises contacting thebaine with a dienophile to form Formula II.
  • Step 2 comprises hydrogenating Formula II to form a compound comprising Formula III.
  • Step 3 comprises contacting the compound of Formula III with t-BuMgX, wherein X is a halogen , to form the compound of Formula IV.
  • Step 4 comprises contacting Formula IV with XCN to form the compound comprising Formula V.
  • Step 5A comprises charging the cyanamide (CMB) with a solvent and ⁇ ! ⁇ to form Formula VI, i.e., Norbuprenorphine 3-Methyl Ether ( ME).
  • CMB cyanamide
  • ME Norbuprenorphine 3-Methyl Ether
  • Step 5B comprises charging a suitable deprotonating base and a suitable base solvent, and RSH compound with Formula VI to form Formula VII, i.e., Norbuprenorphine crude (NOC).
  • Step 5C an optional step, comprises purification of Formula VII, NOC, to form Norbuprenorphine pure (NOP).
  • Step 6 includes contacting Formula VII with cyclopropylmethyl bromide to form buprenorphine base.
  • the yield of buprenorphine base is over about 50 to 80% on going from CMB to NOP. Purity was sufficiently improved by the process of the invention, such that step 5C, the purification step, is optional.
  • stage 5 it has been found that separating stage 5 into two separate steps increases the overall yield of the buprenorphine base. For example but not limitation, it has been found that conducting step 5 in three parts, 5A, 5B, and 5C, with different reactants at milder conditions greatly improves overall yields and limits impurities.
  • the present invention provides an efficient route for synthesizing buprenorphine or its derivatives in high yield and high purity.
  • processes have been discovered that efficiently and with fewer impurity -producing side-reactions convert thebaine or a derivative of thebaine to buprenorphine or a derivative of buprenorphine.
  • the overall yield of buprenorphine or a derivative of buprenorphine can be increased to greater than about 50 to 80% on going from CMB to NOP.
  • the method for preparing buprenorphine or a derivative thereof includes the following Reaction Scheme I.
  • X is a halogen.
  • the solvent is an alcohol, aqueous solution, or a combination thereof.
  • the alcohol can be a diol, such as diethylene glycol, ethylene glycol, or triethylene glycol.
  • M 1 is a metal, including but not limited to Na, K, Li.
  • R is a Ci to C 12 alkyl, branched or straight chain, a cycloalkyl-alkyl-, or an arylalkyl- and isomers thereof, and R 1 is Me-, Et-, nPr-, iPr-, n-Bu- , secBu-, amyl-, and iamyl-.
  • the RSH and R'OM 1 preferably are in a solvent, such as dimethylformamide.
  • the improved process includes an exemplary embodiment as illustrated in Reaction Scheme II below.
  • step 5 is separated into steps 5A, 5B, and 5C.
  • step 5A the product of step 4 is subjected to hydrolysis of the N- cyano group.
  • step 5B norbuprenorphine 3-methyl ether, is subjected to hydrolysis of the 3-O-Me group to produce crude norbuprenorphine.
  • step 5C the crude nor- buprenorphine is purified via its bitartrate salt to pure norbuprenorphine. The steps are further described below.
  • Step 5 A Preparation of Norbuprenorphine 3-Methyl Ether (NME)
  • Step 5A the N-cyano group is removed by hydrolysis.
  • Step 5A comprises contacting CMB with a hydrolysis agent (see Examples 1-3).
  • the hydrolysis agent is a compound having a pKa greater than about 12.0. Suitable compounds include group 1 and group 2 hydroxide salts (such as, for example, KOH and Ca(OH) 2 ); and metal oxides (such as, for example, lithium oxide, magnesium oxide, calcium oxide, and the like).
  • the hydrolysis agent may be a hydroxide of a group 1 or group 2 metal.
  • the hydrolysis agent may be sodium hydroxide.
  • the molar ratio between CMB and the hydrolysis agent can and will vary. Typically, the molar ratio may vary from about 4 to about 8. In some exemplary embodiments, the ratio was 1 :6.
  • the hydrolysis agent may be added to the reaction mixture as a solution of the hydrolysis agent in water.
  • concentration of the hydrolysis agent may range from about 10% to about 100%.
  • the hydrolysis agent may be a 50% solution of sodium hydroxide in water.
  • the CMB may be added to the reaction mixture either in solid form or as a solution in an appropriate organic solvent.
  • CMB was added to the reaction mixture as a solution of CMB in dichloro methane. The solution was extracted from the reaction mixture of the previous step in the overall scheme for preparation of buprenorphine.
  • the hydrolysis reaction mixture also includes an organic solvent.
  • organic solvents are suitable for use in the process of the invention. Suitable organic solvents include, but are not limited to, ethylene glycol, diethylene glycol, triethylene glycol, 2-methoxyethanol, l -methoxy-2-propanol, and combinations thereof. Lower boiling solvents such as methanol, ethanol, n-propanol, i-propanol are also suitable. However, reaction times may be longer and excessive.
  • the solvent may be diethylene glycol.
  • the weight ratio of the solvent to the CMB may vary. In general, the weight ratio of the solvent to the CMB may range from about 2: 1 to about 20: 1.
  • the hydrolysis reaction is conducted at a temperature that ranges from about 65 °C to about 125 °C. In an exemplary embodiment, the reaction is conducted at about 116 °C.
  • the reaction is preferably performed at ambient pressure, and preferably in an inert atmosphere (such as, for example, nitrogen, helium, or argon).
  • an inert atmosphere such as, for example, nitrogen, helium, or argon.
  • the pH of the reaction mixture will be at least about pH 14. In an exemplary embodiment, there is an excess of strong base from beginning to the end, and the pH is always greater than 14.
  • the pH of the mixture may be adjusted with an appropriate pH-modifying agent to attain the desired pH value. Those of skill in the art are familiar with suitable pH-modifying reagents.
  • the reaction is allowed to proceed for a sufficient period of time until the reaction is complete. More specifically, the reaction generally is allowed to proceed until the level of NME no longer increases. Those of skill in the art are familiar with suitable techniques to measure the amount of NME in the reaction mixture. One suitable technique is liquid chromatography. Typically, the reaction is allowed to proceed for a period of time that ranges from about one hour to about 48 hours. In an exemplary embodiment, the reaction is allowed to proceed for 20 hours.
  • water is added to the reaction mixture and the reaction mixture is cooled.
  • the water is added dropwise.
  • the temperature of the reaction mixture is allowed to fall until within the range about 95 °C to about 105 °C.
  • the temperature is allowed to fall until within the range about 95 °C to about 100 °C.
  • the amount of water added to the mixture may vary.
  • the weight ratio of water to the CMB ranges from about 5:1 to about 50: 1.
  • the weight ratio of water to the CMB is 7.7: 1.
  • the reaction mixture is cooled over a period of time to cause precipitation of NME from the reaction mixture.
  • the temperature of the reaction mixture is uniformly reduced until the temperature is within the range about 0 °C to about 10 °C. In an exemplary embodiment, the temperature is uniformly reduced until the temperature is within the range 0 °C to 5 °C.
  • the period of time over which the reaction mixture is cooled may vary. Typically, the reaction mixture is cooled over a period of about 30 minutes to about three hours. In an exemplary embodiment, the reaction mixture is cooled over a period of two hours.
  • the precipitated NME may be easily separated from the reaction mixture using procedures well known to those of skill in the art.
  • Step 5B the 3-O-methyl group is removed to produce crude norbuprenorphine ("NOC").
  • Step 5B comprises contacting NME with an O-demethylation agent (see Examples 4-6).
  • the O-demethylation agent can be, for example, a combination of a mercaptan and a strong organic base. Suitable mercaptans include mercaptans of alkanes, carboxylic acids.
  • the O-demethylation agent may be n- propylmercaptan.
  • the molar ratio between NME and the O-demethylation agent can and will vary. Typically, the molar ratio may vary from about 1 :5 to about 1 : 1. In some exemplary embodiments, the ratio was about 1 :2.
  • Suitable organic bases include lithium, sodium, and potassium salts of alcohols.
  • the organic base was Sodium ieri-butoxide.
  • the O-demethylation reaction includes an organic solvent.
  • organic solvents are suitable for use in the process of the invention. Suitable organic solvents include, but are not limited to, dimethylformamide, dimethylacetamide, N- methylpyrrolidinone, DMSO, sulfolane, other dialkylamide solvents, and combinations, thereof.
  • the solvent was dimethylformamide.
  • the weight ratio of the solvent to the NME may vary. In general, the weight ratio of the solvent to the NME may range from about 2:1 to about 20: 1. In an exemplary embodiment, the weight ratio of the solvent to the NME was about 13:1.
  • the NME, the mercaptan, and the organic base may be added to the reaction mixture. In one particular embodiment, the NME is added last. In an exemplary embodiment, sodium ieri-butoxide was added first, followed by the 1 -propanethiol, followed by NME.
  • the reaction is preferably performed at ambient pressure, and preferably in an inert atmosphere (such as, for example, nitrogen, helium, or argon).
  • an inert atmosphere such as, for example, nitrogen, helium, or argon.
  • the reaction vessel was evacuated to 60 torr and filled with nitrogen three times before charging reactants.
  • the O-demethylation reaction is conducted at a temperature that ranges from about 100 °C to about 125 °C. In an exemplary embodiment, the reaction is conducted at a temperature between 115 and 125°C.
  • the pH of the reaction mixture will be at least about pH 14.
  • the molar amount of base exceeds the molar amount of mercaptan.
  • the reaction is allowed to proceed for a sufficient period of time until the reaction is complete. More specifically, the reaction generally is allowed to proceed until the level of NOC no longer increases. Those of skill in the art are familiar with suitable techniques to measure the amount of NOC in the reaction mixture. One suitable technique is liquid chromatography. Typically, the reaction is allowed to proceed for a period of time that ranges from about one hour to about 48 hours. In an exemplary embodiment, the reaction is allowed to proceed for 12 hours.
  • the reaction mixture Upon completion of the reaction, the reaction mixture is cooled. The temperature of the reaction mixture is allowed to fall until within the range about 60-100 °C. In an exemplary embodiment, the temperature is allowed to fall until about 80 °C.
  • the reaction mixture is quenched by reducing the pH of the reaction mixture.
  • sodium bicarbonate can be added to reduce the pH to approximately 7 or 9, so that strong base will not be an impurity in the precipitated product.
  • the pH lowering agent may be dissolved in water.
  • suitable pH lowering agents include sodium bicarbonate, mineral acid, e.g., dilute hydrochloric or sulfuric, or organic acid, e.g., acetic acid, preferably, the pH reducing agent is sodium bicarbonate.
  • the pH lowering agent was sodium bicarbonate dissolved in water.
  • the pH precipitation occurs over a period of time.
  • the period of time over which the pH precipitation occurs may vary.
  • the pH precipitation occurs over a period of 15 minutes to two hours.
  • the pH precipitation occurred over a course of one hour.
  • the reaction mixture is cooled over a period of time to further encourage precipitation of NOC from the reaction mixture.
  • the temperature of the reaction mixture is uniformly reduced until the temperature is within the range about 0 °C to about 10 °C. In an exemplary embodiment, the temperature is uniformly reduced until the temperature is within the range 0 °C to 5 °C.
  • the period of time over which the reaction mixture is cooled may vary. Typically, the reaction mixture is cooled over a period of about 30 minutes to about three hours. In an exemplary embodiment, the reaction mixture is cooled over a period of two hours.
  • the precipitated NOC may be easily separated from the reaction mixture using procedures well known to those of skill in the art.
  • the NOC thus produced may be used without purification in the sixth and final step of the buprenorphine process described above, or it may be further purified before such use.
  • Step 5C Purification of Crude Norbuprenorphine to Pure
  • step 5C the crude norbuprenorphine is purified to produce pure
  • norbuprenorphine (NOP).
  • the crude norbuprenorphine is purified by converting it to an organic acid salt, followed by production of the purified free-base norbuprenorphine.
  • the organic acid salt is produced by contacting the NOC with an organic acid.
  • the organic acid used to form the salt is a carboxylic acid or a di-carboxylic acid.
  • Suitable acids include tartaric acid.
  • the organic acid was L-tartaric acid.
  • the ratio was about 1 : 1.
  • the salt formation reaction includes an organic solvent.
  • organic solvents are suitable for use in the process of the invention. Suitable organic solvents include, but are not limited to, polar solvents, small alcohols and acetone, and
  • the solvent was isopropyl alcohol.
  • the weight ratio of the solvent to the NOC may vary. In general, the weight ratio of the solvent to the NME may range from about 5: 1 to about 30: 1. In an exemplary
  • the weight ratio of the solvent to the NME was about 20:1.
  • the salt formation reaction is conducted at a temperature that ranges from about 60 °C to 80 °C. In an exemplary embodiment, the reaction was conducted at a temperature between 70 °C and 75 °C.
  • the reaction is allowed to proceed for a sufficient period of time until the reaction is complete. More specifically, the reaction generally is allowed to proceed until cloudiness is seen and crystal formation has begun. If cloudiness is not observed, those of skill in the art are familiar with techniques for seeding crystallization of the reaction system. In an exemplary embodiment, a small amount of the solution was withdrawn and scratched to created seed crystals, then returned to the flask.
  • the reaction mixture Upon completion of the reaction, the reaction mixture is cooled over a period of time to further encourage precipitation of the salt from the reaction mixture.
  • the temperature of the reaction mixture is allowed to fall until within the range about 40-55 °C. In an exemplary embodiment, the temperature is allowed to fall until between 50 °C and 80 °C.
  • the period of time over which the reaction mixture is cooled may vary. Typically, the reaction mixture is cooled over a period of about 30 minutes to about three hours. In an exemplary embodiment, the reaction mixture is cooled over a period of two hours.
  • the precipitated salt may be easily separated from the reaction mixture using procedures well known to those of skill in the art.
  • the salt is converted to NOP by contacting the salt with an inorganic base.
  • the inorganic base is a hydroxide of a group 1 or group 2 metal.
  • the inorganic base may be sodium hydroxide.
  • the base regeneration from the salt reaction uses water as a solvent.
  • the weight ratio of the solvent to the salt may vary. In general, the weight ratio of the solvent to the salt may range from about 20: 1 to about 100: 1. In an exemplary embodiment, the weight ratio of the solvent to the salt was about 47:1.
  • the base regeneration from the salt reaction is conducted at a temperature that ranges from about 40 °C to about 80 °C.
  • the temperature may vary within this range during the course of the reaction.
  • the reaction was conducted at a temperature between 45 °C and 55 °C in an initial portion of the reaction, and between 65 °C and 75 °C in a later portion of the reaction.
  • the inorganic base is added to a solution of the salt to adjust the pH to a value above 9.0.
  • the pH was maintained within the range 9.0 to 9.5. This pH adjustment causes precipitation.
  • the reaction is allowed to proceed at the designated pH for a sufficient period of time until material forms a more readily filterable precipitate. More specifically, the reaction generally is allowed to proceed until the solution becomes thick with precipitate, then thins out. In an exemplary embodiment, this process took twenty minutes.
  • the product of the two hydrolysis steps produces norbuprenorphine.
  • the norburprenorphine is contacted with an agent to form buprenorphine base.
  • the nor-burprenorphine is purified.
  • the present invention provides a process for the preparation of a compound of formula (lb),
  • Rio is a straight-chain, branched or cyclic C1-C20 alkyl
  • R12 is H or CN;
  • Ri3 is a straight-chain, branched or cyclic Ci-C2o-alkyl
  • Ri4 is a straight-chain, branched or cyclic Ci-C2o-alkyl
  • Ri5 is a straight-chain, branched or cyclic Ci-C2o-alkyl and
  • a compound of formula (la) with a thiolate in a suitable polar aprotic solvent, wherein the thiolate is selected from the group consisting of an optionally substituted Ci-C2o-alkylthiolate, an optionally substituted C 6 - C2o-arylthiolate or an optionally substituted C7-C3o-arylalkylthiolate; and ii. treating the reaction mixture of step (i) with a protonating agent to give the compound of formula (lb).
  • Rio is a straight-chain, branched or cyclic C1-C20 alkyl, preferably a straight-chain C1-C20 alkyl. In one embodiment, Rio is a C1-C15 alkyl group, such as a C1-C10 alkyl, for example, a C1-C5 alkyl. In one preferred embodiment, Rio is -Me.
  • R11 is -C(Ri 3 )(Ri 4 )(OH), wherein R 13 and R u are independently straight-chain, branched
  • Ci-C2o-alkyl groups are or cyclic Ci-C2o-alkyl groups.
  • Ri 1 is ' Bu . In another embodiment,
  • Rn is .
  • the keto group may be protected as an acetal or a ketal as described below.
  • R15 is - Me.
  • the O-demethylation step may affect other substituents of the morphinan susceptible to basic conditions or reactive towards nucleophiles, such as keto groups.
  • keto group it is may be desirable to first protect the keto group with a suitable protecting group which may be optionally removed after the O-demethylation step is completed.
  • a suitable protecting group which may be optionally removed after the O-demethylation step is completed.
  • Protecting groups are known in the art and methods for their introduction and removal are described in standard references such as "Greene's Protective Groups in Organic Synthesis", P. G. M. Wuts and T. W. Greene, 4 th Edition, Wiley.
  • Suitable keto protecting groups include but are not limited to acetals and ketals.
  • substituted or unsubstituted, straight-chain or branched Ci-C2o-alkanols substituted or unsubstituted, straight-chain or branched l ,2-(Ci-C2o)-alkyl-diols (for example, ethylene glycol or 1 ,2-propanediol), or substituted or unsubstituted, straight-chain or branched l ,3-(Ci-C2o)-alkyldiols may be conveniently utilized to form suitable acetals or ketals.
  • the process of the present invention can be performed on morphinans comprising unprotected hydroxyl groups.
  • the hydroxy groups may be first protected with a protecting group which may be optionally removed after the O- demethylation step is completed.
  • Suitable protecting groups include but are not limited to alkyl, aryl (e.g. phenyl), benzyl, acyl and silyl groups. Other suitable protecting groups are described in Wuts and Greene above.
  • the process of the present invention may be carried out on morphinans comprising this functional group.
  • morphinans comprising this functional group.
  • is a -C C- double bond.
  • the thiolate is selected from the group consisting of an optionally substituted d- C 2 o-alkylthiolate, an optionally substituted C6-C 2 o-arylthiolate or an optionally substituted C7-C 3 o-arylalkylthiolate. In one preferred embodiment, the thiolate is unsubstituted.
  • the thiolate is substituted.
  • An example of a substituted alkylthiolate is Me0 2 C-CH 2 CH 2 S ⁇ .
  • the alkyl group of the alkylthiolate comprises 2 to 4 carbon atoms, for example, propanethiolate. In another embodiment, the alkyl group of the alkylthiolate comprises greater than 4 carbon atoms, such as 5 or more carbons, for example, 8 or more carbons. In one preferred embodiment, the alkylthiolate is a Cio-C 2 o- alkylthiolate. In one particularly preferred embodiment, the alkylthiolate is a
  • dodecanethiolate salt Unlike other thiolates, the use of dodecanethiolate is advantageous as it is significantly less odorous than other thiolates.
  • a suitable C6-C 2 o-arylthiolate includes but is not limited to phenylthiolate.
  • An example of a suitable C7-C 3 o-arylalkylthiolate includes but is not limited to phenylmethylthiolate.
  • the thiolate may be an alkylthiolate, arylthiolate or arylalkylthiolate tethered to an insoluble support.
  • the insoluble support is a suitable organic support (such as polystyrene).
  • the insoluble support is a suitable inorganic support.
  • the counter cation of the thiolate is typically an alkali metal cation i.e. Li + , Na + or
  • the thiolate may be a commercially available thiolate salt.
  • the thiolate may be prepared from a thiol and a base which is capable of deprotonating the thiol.
  • Suitable bases are generally those where the pKa of the conjugate acid is greater than about four units higher than the pKa of the thiol. In this regard, the approximate pKa of a typical alkylthiol is about 10. Consequently, deprotonation of the alkylthiol may be achieved with the use of a base where the pKa of the conjugate acid is greater than about 14.
  • suitable bases include but are not limited to alkali metal alkoxides (e.g.
  • alkali metal hydroxides such as sodium or potassium hydroxide
  • alkali metal hydrides e.g. sodium hydride
  • organolithium reagents such as butyllithium
  • alkali metal amides e.g. NaNH 2 or K H 2 .
  • the molar ratio between the compound (la) and the thiolate can and will vary. Typically, the molar ratio will vary from about 1 :5 to about 1 : 1. In some exemplary embodiments, the ratio may be about 1 :3, and in others, about 1 :1.5.
  • polar aprotic solvent we mean a liquid medium with a high dielectric constant and dipole moment which does not have an acidic hydrogen.
  • the high polarity of the solvent allows it to dissolve charged species such as nucleophiles (i.e. the thiolate) but the absence of an acidic hydrogen increases the reactivity of nucleophiles as they are less solvated in solution.
  • the polar aprotic solvent is also able to dissolve the compound of formula (la) to form solutions which are preferably in the range of about 0.01-2 mol/L, preferably about 0.05-1.0 mol/L, more preferably about 0.1-0.8 mol/L.
  • the solvent is preferably anhydrous.
  • Suitable polar aprotic solvents preferably have boiling points at atmospheric pressure (i.e. 1.0135xl0 5 Pa) above 140 °C and more preferably above 150 °C.
  • Such solvents generally allow the reaction to be carried out at the optimum temperature to minimize reaction time and impurity generation.
  • Preferred examples are dialkylamide solvents (e.g. dimethylformamide or dimethylacetamide), or cycloalkylamide solvents (e.g. N-methyl-2-pyrrolidone) or combinations thereof.
  • Other examples include dimethylsulfoxide, sulfolane, hexamethylphosphoramide or
  • step (i) is preferably performed at ambient pressure, and preferably in an inert atmosphere (such as, for example, nitrogen, helium or argon).
  • an inert atmosphere such as, for example, nitrogen, helium or argon.
  • the reaction of step (i) may be conducted at a temperature in the range of about 100 °C to about 130 °C. In an exemplary embodiment, the reaction is conducted at a temperature between about 115 °C and about 125 °C.
  • the reaction of step (i) is allowed to proceed for a sufficient period of time until the reaction is complete. More specifically, the reaction generally is allowed to proceed until the level of compound of formula (lb) no longer increases. Those of skill in the art are familiar with suitable techniques to measure the amount of compound (lb) in the reaction mixture. One suitable technique is HPLC. Typically, the reaction is allowed to proceed for a period of time that ranges from about one hour to about 48 hours. In an exemplary embodiment, the reaction is allowed to proceed for 12 hours or less. In certain embodiments, the reaction is allowed to proceed for 6 hours or less.
  • a variety of conditions may be selected in order to help minimize or eliminate the production of impurities by over demethylation at C-6. These conditions include the temperature at which step (i) is conducted and/or the time for which the reaction is allowed to proceed.
  • step (ii) the reaction mixture of step (i) is treated with a protonating agent to give the compound of formula (lb).
  • a protonating agent quenches the 3-O-phenolate anion to provide the compound (lb).
  • Suitable protonating agents include aqueous solutions of an alkali metal bicarbonate (e.g. sodium or potassium bicarbonate).
  • an alkali metal bicarbonate e.g. sodium or potassium bicarbonate
  • the reactants may be added in any suitable order.
  • the compound (la) with a solvent (if used) is added to a reaction mixture of the thiolate in solvent and is reacted for a time and under conditions sufficient for compound (la) to be O-demethylated, followed by the addition of the protonating agent in order to form the compound (lb).
  • reaction mixture may be treated as generally described above in connection with Step 5B, i.e. the preparation of crude
  • the present invention provides a process for the preparation of a compound of formula (lib),
  • R20 and R21 are independently selected from substituted or unsubstituted C1-C20 alkyl or R20 and R21 are interconnected to form a ring;
  • R 22 is H or OH;
  • R23 is selected from the group consisting of H, CN, substituted C1-C20 alkyl, unsubstituted C1-C20 alkyl, substituted C4-C2o-alkyl-cycloalkyl, unsubstituted C 4 - C2o-alkyl-cycloalkyl and allyl;
  • a compound of formula (Ila) with a thiolate in a suitable polar aprotic solvent, wherein the thiolate is selected from the group consisting of an optionally substituted Ci-C2o-alkylthiolate, an optionally substituted C 6 - C2o-arylthiolate or an optionally substituted C7-C3o-arylalkylthiolate; and ii. treating the reaction mixture of step (i) with a protonating agent to give the compound of formula (lib).
  • the two groups may form a ketal as generally described above.
  • R22 is H. In another embodiment, R22 is OH.
  • R2 3 is an unsubstituted C1-C20 alkyl
  • R2 3 is an unsubstituted C1-C20 alkyl
  • the process further comprises converting the compound of formula (lib) to a compound of formula (lie):
  • the compound (lib) may be isolated and optionally purified before being deprotected.
  • the deprotection may be performed by methods known in the art.
  • the 3-O-demethylation conditions of step (i) and/or (ii) may adapted such that the deprotection step also occurs in a one-pot reaction.
  • the present invention provides a process for the preparation of a compound of formula (Illb),
  • R30 is an alcohol protecting group
  • R31 is H or OH
  • R32 is selected from the group consisting of H, CN, substituted C1-C20 alkyl, unsubstituted C1-C20 alkyl, substituted C4-C2o-alkyl-cycloalkyl, unsubstituted C 4 - C2o-alkyl-cycloalkyl and allyl;
  • the process comprising: i. reacting a compound of formula (Ilia) with a thiolate in a suitable polar aprotic solvent, wherein the thiolate is selected from the group consisting of an optionally substituted Ci-C2o-alkylthiolate, an optionally substituted C 6 - C2o-arylthiolate or an optionally substituted C7-C3o-arylalkylthiolate; and ii. treating the reaction mixture of step (i) with a protonating agent to give the compound of formula (Illb).
  • R30 is an alcohol protecting group.
  • R30 is selected from substituted or unsubstituted C1-C20 alkyl.
  • R30 may be a silyl protecting group such as a substituted or unsubstituted (Ci-C2o-alkyl) 3 Si- (such as Me 3 Si- (TMS), l BuMe 2 Si- (TBDMS) or i Pr 3 Si- (TIPS)), a substituted or unsubstituted (Ci-C 2 o-alkyl)(C 6 - C 20 -aryl) 2 Si- (for example, 3 ⁇ 4uPh 2 Si- (TBDPS)) or a substituted or unsubstituted (C1-C20- alkyl) 2 (C 6 -C2o-aryl)Si-.
  • a silyl protecting group such as a substituted or unsubstituted (Ci-C2o-alkyl) 3 Si- (such as Me 3 Si- (TM
  • R31 is H. In another embodiment, R31 is OH.
  • R32 is an unsubstituted C1-C20 alkyl
  • R32 is preferably -Me.
  • R is an unsubstituted C4-C2o-alkyl-c
  • R32 is preferably
  • cyclopropylmethyl- i.e.
  • cyclobutylmethyl- i.e.
  • the compound (Illb) may be deprotected to form a keto group at C-6.
  • the process further comprises converting the compound of formula (Hlb) to a compound of formula (IIIc):
  • the compound (Illb) may be isolated and optionally purified before being deprotected.
  • the deprotection may be performed by methods known in the art.
  • the 3-0-demethylation conditions of step (i) and/or (ii) may adapted such that the deprotection step also occurs in a one-pot reaction.
  • Impurities which may be specified in the Official Monographs for morphinans such as oxymorphone include ⁇ , ⁇ -unsaturated ketones (ABUKs), such as 14- hydroxymorphinone.
  • ABUKs ⁇ , ⁇ -unsaturated ketones
  • Low ABUK oxymorphone may be prepared using the processes of the present invention starting from low ABUK oxycodone.
  • low ABUK oxycodone may be protected to form compounds (Ila) or (Ilia).
  • Low ABUK oxymorphone therefore may be prepared via compounds (lib) or (Illb).
  • the oxymorphone alkaloid prepared according to the present invention comprises ⁇ about 25 ppm of an ⁇ , ⁇ -unsaturated ketone, such as ⁇ about 20 ppm of an ⁇ , ⁇ -unsaturated ketone, for example, ⁇ about 15 ppm of an ⁇ , ⁇ -unsaturated ketone.
  • the oxymorphone alkaloid comprises ⁇ about 10 ppm of an ⁇ , ⁇ -unsaturated ketone.
  • the oxymorphone alkaloid is substantially free of an ⁇ , ⁇ -unsaturated ketone.
  • reaction vessel was carefully purged of nitrogen, with three 60 Torr vacuum-Nitrogen purges. The reaction vessel was thereafter carefully preserved from exposure to the atmosphere. 6.82 g sodium te/ -butoxide (71.0 mmol) was dissolved in 45 mL DMF with stirring, producing a purple solution. 6.7 mL 1 -propanethiol (74.3 mmol) were added via syringe. To this mixture was added a solution of 14.45 g NME (33.79 mmol) in 120 mL warm DMF, followed by a 12 mL DMF rinse. The reaction mixture was heated to 120°C and refiuxed at 1 15-125°C for approximately 12 hours, then allowed to cool to room temperature.
  • the upper aqueous layer was extracted with 17 mL dichloromethane.
  • the combined organic layers were extracted with a solution prepared from 1.3 mL concentrated ammonium hydroxide, 49 mL water, and 10 mL 20% aqueous sodium chloride.
  • the organic layer was then extracted twice more, each time with a solution prepared from 49 mL water and 10 mL 20% aqueous sodium chloride.
  • a flange flask was set up and purged with nitrogen.
  • Sodium tert-butoxide (4.7 g, 0.05 moles) and dimethylformamide (DMF) (31.0 mL, 0.4 moles) were charged to the flask and stirred for 5 minutes. No change in colour was observed.
  • 1 -Propanethiol (5.0 mL, 0.06 moles) was charged. A white precipitate was produced and a slight exotherm was observed. The mixture was stirred for 20 minutes. Meanwhile, a solution of NME (10.0 g, 0.02 moles) in DMF (83.0 mL, 1.07 moles) was prepared. The solution was gently heated to dissolve the solid.
  • the NME solution was charged to the sodium propanthiolate solution followed by a DMF rinse (8.0 mL, 0.1 moles). Whilst stirring, the temperature was increased to 115-125 °C over a period of 30 minutes and held at this temperature range with stirring for 20 hours.
  • alkoxides such as sodium butoxide or ethoxide
  • hydrides such as «-butyllithium
  • amides such as sodium amide
  • Triethylamine was also assessed but only a very low level of product was detected
  • Example 10 The procedure of Example 10 was repeated using N-methyl-2-pyrrolidone (NMP) as the solvent, sodium i-butoxide and propanethiol to give norbuprenorphine (88.71% by area conversion by HPLC) after 18.5 hours reaction time.
  • NMP N-methyl-2-pyrrolidone
  • N-cyano-3-O-methyl-norbuprenorphine was 3-0- demethylated to N-cyano-norbuprenorphine after two hours (77.57% area conversion).
  • LCMS analysis confirmed that the target product has formed. No norbuprenorphine was detected i.e. no cleavage of the cyano group occurred under the reaction conditions.
  • Example 16 Attempted O-Demethylation of other morphinans (comparative) Using the procedure as described in Example 10, the O-demethylations of thebaine, hydrocodone and oxycodone were attempted:
  • oripavine Although some oripavine was formed from thebaine, the reaction was inefficient and an extended reaction time resulted in decomposition or further reaction of the product. As such, opiates containing the diene functionality do not appear to be stable to the demethylation reaction conditions.
  • Oxycodone hydrochloride (30.0 g), ethylene glycol (60 mL, 12.6 eq) and a catalytic amount of para-toluenesulfonic acid (3.24 g, 0.2 eq) in toluene (1200 mL) were heated to reflux with the azeotropic removal of water.
  • the reaction was heated over approx. 30 mins to 1 10 °C and a clear colourless solution was obtained.
  • the reaction mixture was allowed to cool to room temperature and the pH adjusted from pH 6 to pH 9 with 0.88 ammonia solution (7.6 mL).
  • the product was extracted into chloroform, washed with brine and dried over sodium sulfate. The solvent was removed and the product treated with methanol. After removal of the methanol, the white powder was dried to give oxycodone ketal (27.91 g).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de préparation amélioré de buprénorphine, ainsi qu'un procédé visant à accroître le rendement de buprénorphine ou d'un dérivé de celle-ci.
PCT/GB2012/052423 2011-10-03 2012-10-01 Procédé de préparation amélioré de buprénorphine WO2013050748A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA2849988A CA2849988C (fr) 2011-10-03 2012-10-01 Procede de preparation de buprenorphine
US14/349,213 US9624231B2 (en) 2011-10-03 2012-10-01 Method of preparing buprenorphine
IN3197CHN2014 IN2014CN03197A (fr) 2011-10-03 2012-10-01
AU2012320291A AU2012320291B2 (en) 2011-10-03 2012-10-01 Process for preparing buprenorphine
ES12775287.1T ES2692885T3 (es) 2011-10-03 2012-10-01 Proceso para preparar buprenorfina
GB1407259.9A GB2509659B (en) 2011-10-03 2012-10-01 Process for the 3-O-demethylation of morphinan compounds
EP17199667.1A EP3321269B1 (fr) 2011-10-03 2012-10-01 Procédé amélioré de préparation des intermediaires de buprénorphine
EP12775287.1A EP2763996B1 (fr) 2011-10-03 2012-10-01 Procede pour la preparation de buprenorphine
ZA2014/02624A ZA201402624B (en) 2011-10-03 2014-04-10 Process for preparing buprenorphine
US15/489,146 US10208054B2 (en) 2011-10-03 2017-04-17 Method of preparing buprenorphine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542491P 2011-10-03 2011-10-03
US61/542,491 2011-10-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/349,213 A-371-Of-International US9624231B2 (en) 2011-10-03 2012-10-01 Method of preparing buprenorphine
US15/489,146 Division US10208054B2 (en) 2011-10-03 2017-04-17 Method of preparing buprenorphine

Publications (2)

Publication Number Publication Date
WO2013050748A2 true WO2013050748A2 (fr) 2013-04-11
WO2013050748A3 WO2013050748A3 (fr) 2013-11-07

Family

ID=47046640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/052423 WO2013050748A2 (fr) 2011-10-03 2012-10-01 Procédé de préparation amélioré de buprénorphine

Country Status (11)

Country Link
US (2) US9624231B2 (fr)
EP (2) EP3321269B1 (fr)
AU (1) AU2012320291B2 (fr)
CA (2) CA2849988C (fr)
ES (2) ES2805655T3 (fr)
GB (2) GB2509659B (fr)
HU (2) HUE040284T2 (fr)
IN (1) IN2014CN03197A (fr)
PT (2) PT3321269T (fr)
WO (1) WO2013050748A2 (fr)
ZA (1) ZA201402624B (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813507A1 (fr) 2013-06-11 2014-12-17 Rusan Pharma Limited Procédé industriel pour la préparation de buprénorphine et de ses intermédiaires
WO2015171354A2 (fr) 2014-05-05 2015-11-12 Noramco, Inc. Procédé de préparation de composés opioïdes
WO2015171353A3 (fr) * 2014-05-05 2016-03-10 Noramco, Inc. Procédé de préparation de composés opioïdes
WO2017074904A1 (fr) * 2015-10-26 2017-05-04 Orphomed, Inc. Éther de l'éthylèneglycol de buprénorphine
WO2019009820A1 (fr) 2017-07-04 2019-01-10 Saneca Pharmaceuticals A.S. Procédé de préparation de composés de morphinane
EP3371193A4 (fr) * 2015-10-12 2019-03-20 Noramco, Inc. Procédé de préparation de (s)-2-((4r,4as, 6r,7ar,12bs)-7,9-diméthoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-éthano-4, 12-méthanobenzofuro[3,2-e]isoquinoléin-6-yl)-3,3-diméthylbutan-2-ol
WO2021151908A1 (fr) * 2020-01-27 2021-08-05 Azad Pharma Ag Procédé de synthèse de buprénorphine
CN113956263A (zh) * 2021-12-06 2022-01-21 四川大学 一种吗啡衍生物丁丙诺啡的合成方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3238849A1 (fr) 2021-12-16 2023-06-22 Arevipharma Gmbh Procede de fabrication de buprenorphine et des composes precurseurs de celle-ci

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100087647A1 (en) 2008-09-30 2010-04-08 Mallinckrodt Inc. Processes for the production of buprenorphine with reduced impurity formation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474101A (en) * 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
FR2554816B1 (fr) * 1983-11-16 1986-09-26 Sanofi Sa Nouveau derive de la nororipavine presentant a la fois une activite agoniste et antagoniste des recepteurs morphiniques
KR100204659B1 (ko) * 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
MX2009005461A (es) * 2006-11-22 2009-08-28 Progenics Pharm Inc N-oxidos de analogos de 4,5-epoxi-morfinano.
US7928234B2 (en) * 2007-06-29 2011-04-19 Brock University Conversion of thebaine to morphine derivatives
US8962841B2 (en) 2007-06-29 2015-02-24 Brock University Methods for one-pot N-demethylation/N-functionalization of morphine and tropane alkaloids
WO2009067275A1 (fr) * 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxydes d'analogues 4,5-époxy-morphinanium
AU2009233315B2 (en) * 2008-03-31 2013-08-29 Sun Pharmaceutical Industries Ltd. An improved process for the preparation of morphinane analogues
WO2009132313A2 (fr) * 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Dérivés de morphinane d’acides organiques et inorganiques
EP2344507B2 (fr) * 2008-09-30 2021-05-26 Mallinckrodt LLC Procédés d`augmentation du rendement de l'hydrolyse du groupe 3-o-méthyle et 17-n-nitrile dans la préparation de dérivés alcaloïdes opiacés
GB201111775D0 (en) * 2011-07-08 2011-08-24 Univ Bath Compounds and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100087647A1 (en) 2008-09-30 2010-04-08 Mallinckrodt Inc. Processes for the production of buprenorphine with reduced impurity formation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P. G. M. WUTS; T. W. GREENE: "Greene's Protective Groups in Organic Synthesis", WILEY

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813507A1 (fr) 2013-06-11 2014-12-17 Rusan Pharma Limited Procédé industriel pour la préparation de buprénorphine et de ses intermédiaires
US8981097B2 (en) 2013-06-11 2015-03-17 Rusan Pharma Limited Industrial process for the preparation of buprenorphine and its intermediates
AU2015256507B2 (en) * 2014-05-05 2019-11-21 Noramco, Llc Process for the preparation of opioid compounds
WO2015171354A2 (fr) 2014-05-05 2015-11-12 Noramco, Inc. Procédé de préparation de composés opioïdes
WO2015171354A3 (fr) * 2014-05-05 2016-03-17 Noramco, Inc. Procédé de préparation de composés opioïdes
JP2020203872A (ja) * 2014-05-05 2020-12-24 ノランコ・エルエルシー オピオイド化合物を調製するプロセス
JP2017514845A (ja) * 2014-05-05 2017-06-08 ノランコ・インコーポレーテツドＮｏｒａｍｃｏ Ｉｎｃｏｒｐｏｒａｔｅｄ オピオイド化合物を調製するプロセス
JP2017514846A (ja) * 2014-05-05 2017-06-08 ノランコ・インコーポレーテツドＮｏｒａｍｃｏ Ｉｎｃｏｒｐｏｒａｔｅｄ オピオイド化合物を調製するプロセス
US9701687B2 (en) 2014-05-05 2017-07-11 Noramco, Inc. Process for the preparation of opioid compounds
US9701688B2 (en) 2014-05-05 2017-07-11 Noramco, Inc. Process for the preparation of opioid compounds
CN107074869A (zh) * 2014-05-05 2017-08-18 诺拉姆科有限公司 制备阿片类化合物的方法
WO2015171353A3 (fr) * 2014-05-05 2016-03-10 Noramco, Inc. Procédé de préparation de composés opioïdes
EP3371193A4 (fr) * 2015-10-12 2019-03-20 Noramco, Inc. Procédé de préparation de (s)-2-((4r,4as, 6r,7ar,12bs)-7,9-diméthoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-éthano-4, 12-méthanobenzofuro[3,2-e]isoquinoléin-6-yl)-3,3-diméthylbutan-2-ol
US10287296B2 (en) 2015-10-12 2019-05-14 Noramco, Inc. Process for the preparation of (S)-2-((4R,4aS,6R,7R,7aR,12bS)-7,9-dimethoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-6-yl)-3,3-dimethylbutan-2-ol
CN108289887A (zh) * 2015-10-26 2018-07-17 奥佛麦德公司 丁丙诺啡的乙二醇醚
WO2017074904A1 (fr) * 2015-10-26 2017-05-04 Orphomed, Inc. Éther de l'éthylèneglycol de buprénorphine
WO2019009820A1 (fr) 2017-07-04 2019-01-10 Saneca Pharmaceuticals A.S. Procédé de préparation de composés de morphinane
WO2021151908A1 (fr) * 2020-01-27 2021-08-05 Azad Pharma Ag Procédé de synthèse de buprénorphine
US11905296B2 (en) 2020-01-27 2024-02-20 Azad Pharma Ag Process for the synthesis of buprenorphine
EP4335853A3 (fr) * 2020-01-27 2024-04-24 AZAD Pharma AG Procédé de synthèse de buprénorphine
CN113956263A (zh) * 2021-12-06 2022-01-21 四川大学 一种吗啡衍生物丁丙诺啡的合成方法

Also Published As

Publication number Publication date
HUE040284T2 (hu) 2019-02-28
ES2692885T3 (es) 2018-12-05
GB201810013D0 (en) 2018-08-01
WO2013050748A3 (fr) 2013-11-07
GB2509659A (en) 2014-07-09
PT2763996T (pt) 2018-11-09
PT3321269T (pt) 2020-07-24
EP3321269A1 (fr) 2018-05-16
ZA201402624B (en) 2017-05-31
US9624231B2 (en) 2017-04-18
EP2763996B1 (fr) 2018-07-25
CA2849988C (fr) 2019-09-10
CA3026884C (fr) 2020-10-27
CA3026884A1 (fr) 2013-04-11
US20140235860A1 (en) 2014-08-21
GB2560284B (en) 2019-01-09
HUE048899T2 (hu) 2020-08-28
GB2560284A (en) 2018-09-05
AU2012320291A1 (en) 2014-04-17
IN2014CN03197A (fr) 2015-07-03
GB201407259D0 (en) 2014-06-11
GB2560284A8 (en) 2018-10-10
GB2509659B (en) 2019-01-09
EP2763996A2 (fr) 2014-08-13
EP3321269B1 (fr) 2020-04-29
US10208054B2 (en) 2019-02-19
US20170217978A1 (en) 2017-08-03
AU2012320291B2 (en) 2015-06-18
ES2805655T3 (es) 2021-02-15
CA2849988A1 (fr) 2013-04-11

Similar Documents

Publication Publication Date Title
US10208054B2 (en) Method of preparing buprenorphine
US8080661B2 (en) Processes for the synthesis of tertiary amines
CA2738761A1 (fr) Procedes de production de buprenorphine avec formation reduite d'impuretes
AU2009300384B2 (en) Processes for increasing the yield of opiate alkaloid derivatives
EP2417139B1 (fr) Préparation de composés cétone saturée morphinanes par isomérisation catalytique
US8232398B2 (en) Recycling process for increasing the yield of opiate alkaloid derivatives
EP2328899B1 (fr) Procédés de synthèse de cycles hétérocycliques à cinq et six chaînons
WO2009111162A1 (fr) Procédé de préparation de dérivés de 3-hydroxy-morphinane
CA2738305C (fr) Procedes de synthese d'alcaloides opiaces avec formation reduite d'impuretes
EP2601195A1 (fr) Processus tandem pour préparer des n-alkyl morphinanes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12775287

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2849988

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14349213

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2012320291

Country of ref document: AU

Date of ref document: 20121001

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1407259

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20121001

WWE Wipo information: entry into national phase

Ref document number: 1407259.9

Country of ref document: GB

Ref document number: 2012775287

Country of ref document: EP